The present disclosure relates to an IL-33 antagonist for use in the prevention or treatment of abnormal epithelium physiology or EGFR-mediated diseases, and corresponding methods of prevention or treatment comprising administering an IL-33 antagonist to a patient in need thereof.

The present disclosure is directed to a method of treating nonalcoholic fatty liver disease (NAFLD), and subsets thereof such as nonalcoholic steatohepatitis (NASH), using an IL-17 antagonist, such as a monoclonal antibody that specifically binds to IL-17 receptor A (IL-17RA).

The disclosure provides methods of treating a malignancy comprising administering an effective dose of an immune cell therapy (e.g., a chimeric antigen receptor genetically modified T cell immunotherapy) and methods for manufacturing such immunotherapy. Some aspects of the disclosure relate to methods of determining objective response of a patient to an immune cell immunotherapy based on the levels of patient and product attributes prior to and after administration of the immunotherapy to the patient.

Provided herein are anti-FLT3L antibodies and methods of using the antibodies to treat autoimmune and other inflammatory diseases.

Provided herein are methods and devices related to inducing a population of self-renewing or senescent stem cells, to produce one or more beneficial factors for the treatment of a disease or disorder in an individual. Also provided are compositions and methods for inducing senescence, useful for inducing senescence in a population of stem cells, in order to produce one or more beneficial factors for the treatment of a disease or disorder in an individual. Methods and devices to control and customize the production of the beneficial factors for the requirements of a disease or disorder being treated are described. Also provided are factor production units for the production of the beneficial factors, and devices for the delivery of the beneficial factors to an individual in need.

The present disclosure relates to aqueous compositions for anti-IL17a antibodies, and more particularly to aqueous compositions for anti-IL17a antibodies with a V.sub.HH variable domain and a V.sub.L variable domain, and can be used as a medicinal agent for treating IL-17A-mediated diseases.

This document relates to methods and materials for targeted expansion of immune effector (Eff) T cells. For example, a composition containing one or more amino acid chains (e.g., one or more single-chain antibody/cytokine fusion proteins (immunocytokines)) that can bind to a heterodimeric receptor including an interleukin-2 receptor-β (IL-2Rβ) polypeptide and a common gamma chain (γ.sub.c) polypeptide (e.g., an IL-2Rβ/γ.sub.c polypeptide complex) can be administered to a mammal to stimulate Effs within the mammal to activate an immune response in that mammal. In some cases, methods and materials that can be used to treat a mammal having a condition that can benefit from activating an immune response (e.g., a cancer and/or an infectious disease) are provided. For example, a composition containing one or more single-chain immunocytokines that can bind to an IL-2Rβ/γ.sub.c polypeptide complex can be administered to a mammal having a cancer and/or an infectious disease to treat the mammal.

A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNFα inhibitor, such as an anti-TNFα antibody (e.g., golimumab).

The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an anti-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.

The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.